NuCana Terminates Mid-Stage Colorectal Cancer Trial Due to Disappointing Results

Trial Termination: NuCana plc has discontinued its Phase 2 NuTide:
323 trial for a chemotherapy derivative, NUC-3373, in combination with leucovorin, irinotecan, and bevacizumab, due to disappointing results.

Reason for Termination:
The trial was stopped after a pre-planned initial analysis and recommendation from the Study Steering Committee, which concluded that the combination was unlikely to meet the primary goal of demonstrating superior Progression-Free Survival compared to the control treatment.

Safety Profile:
Despite the trial's failure, the treatment regimens were reported to have a favorable safety profile and were generally well tolerated, with only 12 out of 175 participants discontinuing treatment due to adverse effects.

Impact on Other Trials: The results of the NuTide:323 study do not affect the ongoing NuTide:
303 trial, where NUC-3373 is being evaluated in combination with pembrolizumab for solid tumors or docetaxel for lung cancer patients.

Future Plans:
NuCana remains committed to improving survival outcomes for patients with cancer and is excited about the potential of NUC-7738, a novel agent that impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment.

Stock Impact:
NuCana's stock price plummeted nearly 50% in pre-market trading following the announcement.